Abstract
Heparan sulfate proteoglycans (HSPGs) were isolated from normal human liver and a monoclonal antibody (MAb) was raised against them. Preliminary studies showed that MAb clone 1E4-1C2 was able to react with many cell lines tested, including hematopoietic cells and solid tumors. MAb1E4-1C2 was used to study whether HSPG was involved in growth and proliferation of human liver cancer using hepatocellular carcinoma (HCC) cell line (HepG2) as a model. Inhibition by MAb1E4-1C2 of HepG2 cell proliferation was studied in vitro by MTT assay. For in vivo assay, xenograft induction in athymic mice was performed. The results showed that MAb1E4-1C2 inhibited proliferation of HepG2 cells significantly, compared to isotype and medium control. MAb1E4-1C2 also suppressed the growth of tumor, resulting in smaller tumor size and weight. The investigation also showed that MAb1E4-1C2 inhibited proliferation and restricted tumor growth through the induction of apoptosis. The results suggest that HSPG might be involved in liver cancer cell proliferation. Therefore, a specific MAb that was raised against liver HSPG might be an alternative therapeutic agent for the treatment of human liver cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 4067-4074 |
| Number of pages | 8 |
| Journal | Anticancer Research |
| Volume | 31 |
| Issue number | 12 |
| State | Published - Dec 2011 |
| Externally published | Yes |
Keywords
- HepG2 cells
- Heparan sulfate
- Immunotherapy
- Liver cancer
- Proteoglycans
- Xenograft
Fingerprint
Dive into the research topics of 'Inhibition of human tumor xenograft growth in nude mice by a novel monoclonal anti-HSPG isolated from human liver'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver